DMAC RSI Chart
Last 7 days
2.4%
Last 30 days
-6.2%
Last 90 days
-4.5%
Trailing 12 Months
61.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2020 | 797.0K | 636.0K | 398.0K | 205.0K |
2019 | 589.0K | 678.0K | 767.0K | 856.0K |
2018 | 0 | 0 | 0 | 500.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 02, 2024 | pilnik richard d. | acquired | 84,999 | 2.8 | 30,357 | - |
Jan 02, 2024 | semba charles pauling | acquired | 26,250 | 2.8 | 9,375 | - |
Jan 02, 2024 | parsons james t. | acquired | 59,998 | 2.8 | 21,428 | - |
Jan 02, 2024 | giuffre randall michael | acquired | 53,748 | 2.8 | 19,196 | - |
Jan 02, 2024 | kuntz richard | acquired | 39,998 | 2.8 | 14,285 | - |
Nov 16, 2023 | wambeke david j. | bought | 49,200 | 2.46 | 20,000 | chief business officer |
Jun 23, 2023 | von koch thomas | bought | 5,000,000 | 3.4 | 1,470,590 | - |
Jun 23, 2023 | semba charles pauling | bought | 49,997 | 3.91 | 12,787 | - |
Jun 23, 2023 | pauls dietrich john | bought | 49,997 | 3.91 | 12,787 | president and ceo |
Jun 23, 2023 | pilnik richard d. | bought | 149,999 | 3.91 | 38,363 | - |
Which funds bought or sold DMAC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -1,000 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -29.89 | -30,742 | 66,479 | -% |
Apr 23, 2024 | CATALYST FINANCIAL PARTNERS LLC | unchanged | - | -8,704 | 94,294 | 0.02% |
Apr 17, 2024 | Legend Financial Advisors, Inc. | unchanged | - | -70.00 | 2,770 | -% |
Apr 09, 2024 | MASSMUTUAL TRUST CO FSB/ADV | unchanged | - | -338 | 13,362 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.7 | 243,090 | 2,278,160 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 67,481 | 67,481 | -% |
Feb 14, 2024 | Royal Bank of Canada | added | 34.41 | 1,000 | 3,000 | -% |
Feb 14, 2024 | PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | added | 6.38 | 207,400 | 1,420,000 | 3.26% |
Feb 14, 2024 | BNP PARIBAS FINANCIAL MARKETS | unchanged | - | 3,640 | 39,760 | -% |
Unveiling DiaMedica Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to DiaMedica Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.6B | 6.8B | -8.61 | 5.92 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.1 | 9.9 | ||||
BMRN | 15.5B | 2.4B | 92.47 | 6.41 | ||||
INCY | 11.5B | 3.7B | 19.23 | 3.11 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.93 | 14.57 | ||||
BBIO | 4.3B | - | -6.55 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.16 | 12.52 | ||||
ARWR | 2.7B | 240.7M | -9.13 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -43.85 | 3.7 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.23 | 4.35 | ||||
NVAX | 552.8M | 983.7M | -1.01 | 0.56 | ||||
CRBP | 351.2M | 881.7K | -7.87 | 466.16 | ||||
INO | 236.5M | 4.9M | -1.75 | 48.6 | ||||
IBIO | 5.9M | 2.1M | -0.22 | 2.14 |
DiaMedica Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -100.0% | - | 25.00 | 65.00 | 115 | 193 | 263 | 226 | 174 | 337 | 500 |
Operating Expenses | - | - | - | - | - | - | - | - | 3,421 | - | - |
S&GA Expenses | 0.8% | 1,171 | 1,161 | 1,108 | 1,055 | 968 | 1,044 | 867 | 814 | 667 | 777 |
R&D Expenses | 43.5% | 3,098 | 2,158 | 1,600 | 1,349 | 1,802 | 1,617 | 1,874 | 2,607 | 1,451 | 1,210 |
Income Taxes | 250.0% | 7.00 | 2.00 | 9.00 | 9.00 | 2.00 | 12.00 | 8.00 | 9.00 | 6.00 | 57.00 |
Earnings Before Taxes | -31.4% | -4,193 | -3,191 | -2,465 | -2,416 | -2,478 | -2,436 | -2,461 | -3,243 | -1,956 | -1,330 |
Net Income | -31.5% | -4,200 | -3,193 | -2,474 | -2,425 | -2,480 | -2,448 | -2,469 | -3,252 | -1,962 | -1,387 |
Free Cashflow | -Infinity% | -3,061 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -6.8% | 54.00 | 58.00 | 62.00 | 30.00 | 34.00 | 37.00 | 39.00 | 42.00 | 46.00 | 49.00 | 22.00 | 24.00 | 28.00 | 31.00 | 13.00 | 14.00 | 9.00 | 11.00 | 13.00 | 15.00 | 18.00 |
Current Assets | 12.1% | 54.00 | 48.00 | 41.00 | 30.00 | 34.00 | 36.00 | 39.00 | 42.00 | 45.00 | 49.00 | 22.00 | 24.00 | 28.00 | 31.00 | 12.00 | 14.00 | 9.00 | 11.00 | 12.00 | 15.00 | 18.00 |
Cash Equivalents | 103.5% | 5.00 | 2.00 | 6.00 | 2.00 | 5.00 | 3.00 | 3.00 | 3.00 | 5.00 | 16.00 | 2.00 | 3.00 | 7.00 | 10.00 | 5.00 | 3.00 | 4.00 | 5.00 | 3.00 | 3.00 | 17.00 |
Net PPE | -3.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Current Liabilities | 28.4% | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Shareholder's Equity | -8.2% | 51.00 | 56.00 | 60.00 | 27.00 | 32.00 | 35.00 | 38.00 | 41.00 | 44.00 | 47.00 | 20.00 | 23.00 | 26.00 | 30.00 | 11.00 | 13.00 | 8.00 | 10.00 | 12.00 | 14.00 | 17.00 |
Retained Earnings | -4.7% | -115 | -110 | -105 | -101 | -96.18 | -92.40 | -89.40 | -86.01 | -82.50 | -79.25 | -75.81 | -72.53 | -68.91 | -64.71 | -61.52 | -59.04 | -56.62 | -54.14 | -51.69 | -49.22 | -45.97 |
Additional Paid-In Capital | 0.3% | 167 | 166 | 166 | 129 | 128 | 128 | 127 | 127 | 127 | 126 | 96.00 | 96.00 | 95.00 | 94.00 | 73.00 | 72.00 | 64.00 | 64.00 | 63.00 | 63.00 | 63.00 |
Shares Outstanding | 0.0% | 38.00 | 38.00 | 38.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 19.00 | 19.00 | 19.00 | - | - | - | - | - | - | - | - | - |
Float | - | 103 | - | - | - | 53.00 | - | - | - | - | - | 78.00 | - | - | - | 79.00 | - | - | - | 53.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 21.1% | -3,784 | -4,797 | -5,030 | -5,089 | -2,766 | -2,361 | -2,496 | -3,888 | -2,804 | -3,046 | -2,089 | -4,313 | -3,016 | -2,347 | -844 | -2,978 | -1,865 | -1,232 | -2,871 | -3,134 | -1,900 |
Share Based Compensation | 7.3% | 456 | 425 | 380 | 422 | 411 | 418 | 365 | 308 | 298 | 303 | 446 | 511 | 506 | 508 | 436 | 393 | 401 | 451 | 182 | 130 | 65.00 |
Cashflow From Investing | 412.0% | 6,124 | 1,196 | -28,128 | 2,509 | 4,724 | 2,072 | 2,528 | 2,214 | -8,689 | -12,828 | 989 | -9.00 | 667 | -14,000 | 2,500 | -5,301 | 1,008 | 3,000 | 3,012 | -10,928 | 13.00 |
Cashflow From Financing | 83.3% | -1.00 | -6.00 | 36,850 | -1.00 | -1.00 | -2.00 | -2.00 | -1.00 | -19.00 | 29,865 | -1.00 | 242 | -39.00 | 21,189 | -1.00 | 7,696 | -1.00 | -1.00 | 74.00 | -2.00 | 14,812 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Research and development | $ 13,110 | $ 7,839 |
General and administrative | 8,157 | 6,162 |
Total operating expenses | 21,267 | 14,001 |
Operating loss | (21,267) | (14,001) |
Other income, net | 1,929 | 353 |
Total other income, net | 1,929 | 353 |
Loss before income tax expense | (19,338) | (13,648) |
Income tax expense | (43) | (28) |
Net loss | (19,381) | (13,676) |
Unrealized gain (loss) on marketable securities | 80 | (23) |
Net loss and comprehensive loss | $ (19,301) | $ (13,699) |
Basic and diluted net loss per share (in dollars per share) | $ (0.6) | $ (0.52) |
Weighted average shares outstanding – basic and diluted (in shares) | 32,566,723 | 26,443,067 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,543 | $ 4,728 |
Marketable securities | 48,352 | 28,774 |
Prepaid expenses and other assets | 411 | 251 |
Amounts receivable | 369 | 82 |
Total current assets | 53,675 | 33,835 |
Non-current assets: | ||
Operating lease right-of-use asset | 354 | 424 |
Property and equipment, net | 131 | 136 |
Total non-current assets | 485 | 560 |
Total assets | 54,160 | 34,395 |
Current liabilities: | ||
Accounts payable | 926 | 734 |
Accrued liabilities | 1,777 | 1,365 |
Finance lease obligation | 3 | 6 |
Operating lease obligation | 80 | 63 |
Total current liabilities | 2,786 | 2,168 |
Non-current liabilities: | ||
Finance lease obligation, non-current | 1 | 4 |
Operating lease obligation, non-current | 316 | 396 |
Total non-current liabilities | 317 | 400 |
Commitments and Contingencies | ||
Shareholders' equity | ||
Common shares, no par value; unlimited authorized; 37,958,000 and 26,443,067 shares issued and outstanding, as of December 31, 2023 and 2022, respectively | 0 | 0 |
Paid-in capital | 166,609 | 128,078 |
Accumulated other comprehensive income (loss) | 6 | (74) |
Accumulated deficit | (115,558) | (96,177) |
Total shareholders’ equity | 51,057 | 31,827 |
Total liabilities and shareholders’ equity | $ 54,160 | $ 34,395 |